A subsequent study reported that a selective blockade of the primary 2-AG metabolising enzyme monoacylglycerol lipase (MGL), either by use of the selective MGL inhibitor JZL184 or by shRNA knockdown of the enzyme, affected cell survival and invasion in vitro and reduced tumour growth in a xenograft model [3]. This evidence concerns the gene MGLL and neoplasm.